News

Fitbit device used to inform ER treatment

BY Michael Johnsen

 

WASHINGTON – Emergency physicians used a patient's personal activity tracker and smartphone to identify the time his heart arrhythmia started, which allowed them to treat his new-onset atrial fibrillation with electrical cardioversion and discharge him home. It's the first case report using information in an activity tracker/smartphone system to assist in medical decision-making and was reported online Friday in Annals of Emergency Medicine
 
"Using the patient's activity tracker – in this case, a Fitbit – we were able to pinpoint exactly when the patient's normal heart rate of 70 jumped up to 190," said corresponding study author Alfred Sacchetti, a doctor with Our Lady of Lourdes Medical Center in Camden, N.J. "The device told us that the patient's atrial fibrillation was present for only a few hours. That was well within the 48-hour window needed to consider him for rhythm conversion, so we cardioverted him and sent him home."
 
A 42-year-old patient with a history of seizures but no history of cardiac disease or prior episodes of atrial fibrillation came to the emergency department following a seizure. He had an irregular heart rate ranging between 130 and 190 beats per minute. He was medicated with oxcarbazepine and diltiazem. His heart rate returned to normal (between 80 and 100 beats per minute) but the atrial fibrillation remained.
 
The treatment of recent onset atrial fibrillation is electrical cardioversion in any patient who can reliably relate an arrhythmia onset time of within the previous 48 hours. Because the patient was asymptomatic during his current episode of atrial fibrillation, it was not possible to assign an onset time for his arrhythmia.
 
Emergency department staff accessed the smartphone application connected with his activity tracker and discovered the onset time for his atrial fibrillation was 3 hours prior to coming to the emergency department. After cardioverting the sedated patient, emergency department staff interrogated the smartphone app again, which accurately recorded the change in heart rate consistent with a rhythm change from atrial fibrillation to normal rhythm. The patient was discharged home with instructions to follow up with outpatient cardiology.
 
"Not all activity trackers measure heart rates, but this is the function of most value to medical providers," Sacchetti said. "Dizziness with a heart rate of 180 would be approached very differently from the same complaint with a heart rate of 30. At present, activity trackers are not considered approved medical devices and use of their information to make medical decisions is at the clinician's own discretion. However, the increased use of these devices has the potential to provide emergency physicians with objective clinical information prior to the patient's arrival at the emergency department."
 
 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Report: Sam’s Club seeks higher-net worth members

BY Gina Acosta
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Lupin names president for Lupin-Somerset division

BY Gina Acosta

BALTIMORE and MUMBAI — Lupin on Wednesday announced the appointment of Dr. Kurt Nielsen as president of Lupin-Somerset.

Nielsen will be in charge of overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, N.J.

"Kurt joins us at an exciting phase of Lupin's evolution as a global generics powerhouse and an emerging specialty pharmaceutical company, having closed the Gavis acquisition recently," said Vinita Gupta, CEO, Lupin Limited. "We have ambitious plans to further strengthen and expand our generic as well as specialty business in the U.S. I am confident that Kurt's leadership, knowledge and rich experience will help accelerate growth momentum and meet and exceed the ambitious targets that we have set for ourselves. We are delighted to have Kurt join the Lupin family."

Nielsen has more than 20 years of rich experience in creating, managing high growth businesses; research, development and launching new products in the U.S.; and managing transactions and business development.

Nielsen joins Lupin from Sandoz, where he held dual responsibility of being the global head of product development as well as being the VP of U.S. product development, portfolio and launch management for generic and brand products.

Having started his pharmaceutical career at Johnson & Johnson, Nielsen's previous leadership roles include being the chief technology officer & SVP at Catalent Pharma Solutions, responsible for their global R&D efforts; SVP in-charge of R&D, technology, including manufacturing and quality at URL Mutual Pharmaceuticals; and being the ED of generic R&D at TEVA Pharmaceuticals.

He holds a Ph.D in Chemistry from the Villanova University and has a BS in Chemistry from the University of Delaware.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?